
Sign up to save your podcasts
Or


Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: dx.doi.org/10.1136/lupus-2022-000763
By BMJ Group4
1515 ratings
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: dx.doi.org/10.1136/lupus-2022-000763

497 Listeners

36 Listeners

48 Listeners

5 Listeners

7 Listeners

6 Listeners

3 Listeners

2 Listeners

3 Listeners

9 Listeners

40 Listeners

14 Listeners

1 Listeners

48 Listeners

0 Listeners

6 Listeners

28,586 Listeners

500 Listeners

131 Listeners

3 Listeners

20 Listeners

16,920 Listeners

33,452 Listeners

9,241 Listeners

23 Listeners

27,558 Listeners

31 Listeners

4 Listeners

19,831 Listeners

2 Listeners

46 Listeners

0 Listeners

1,621 Listeners

681 Listeners